YAKUGAKU ZASSHI
Online ISSN : 1347-5231
Print ISSN : 0031-6903
早期公開論文
早期公開論文の2件中1~2を表示しています
  • 堀 英生, 菊池 千草, 今枝 憲郎, 岡山 直司, 鈴木 匡, 松永 民秀
    論文ID: 18-00218
    発行日: 2019年
    [早期公開] 公開日: 2019/02/15
    ジャーナル フリー 早期公開

    It is reported that statins have inconsistent effects on glycemic status and adiponectin concentrations in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effect of statins on these variables in patients with T2DM and hypercholesterolemia. A control group comprising 24 patients with T2DM but without hypercholesterolemia was observed for more than 12 weeks, while 24 patients with T2DM and hypercholesterolemia were treated with statins for the same period (statin group). The percentage changes in the glycemic status (blood glucose and glycated hemoglobin [HbA1c]), and levels of plasma adiponectin (total and high molecular weight [HMW]) were compared between the two groups. The statin group had reduced percentage changes in HbA1c, blood glucose, and total and HMW-adiponectin concentration percentage changes that were similar to those in the control group. However, when matched for sex, age (± 5 years) and HbA1c (± 0.5%) with the control group, the pravastatin group had reduced percentage changes in the plasma HMW-adiponectin concentrations than the matched controls (p = 0.023). However, there were no differences in the percentage changes in the plasma total adiponectin (p = 0.137), HbA1c (p = 0.202), or blood glucose concentrations (p = 0.450) between the two groups. Pravastatin treatment had no effect on the glycemic status of patients with T2DM and hypercholesterolemia, but may reduce the percentage changes in the plasma HMW-adiponectin concentrations. Hence, patients with T2DM and hypercholesterolemia receiving long-term treatment with pravastatin might experience increased insulin resistance.

  • 岩出 賢太郎, 下路 静佳, 正木 秀典, 酒井 隆全, 田辺 公一, 後藤 伸之, 大津 史子
    論文ID: 18-00205
    発行日: 2018年
    [早期公開] 公開日: 2018/12/05
    ジャーナル フリー 早期公開

    We investigated the possibility that having pharmacists give asthma patients informational sheets on climate and environmental changes at insurance pharmacies during patient counseling might prevent the worsening of asthma symptoms. Patients with hyperlipidemia were comparative subjects. We created informational sheets about climate and environmental changes and their influence on asthma. During patient counseling, pharmacists gave them to all asthma patients who visited insurance pharmacies over a period of 2 months, between November and December 2017. Based on previous studies, we called days which showed certain climate or environmental changes as compared to the previous day “change days”. We compared the number of visiting patients on change days after preventative information was provided (between January and March 2018) with the number before information was provided (between January and March 2017). In addition, we compared those numbers with the number of patients who visited the target pharmacies between January and March 2016 in order to examine the influence of yearly climate change. The same procedure was used with hyperlipidemic patients. The number of visiting asthma patients after information was provided significantly decreased (5.1±2.1, p=0.03) compared with the number before information was provided, between January and March 2017 (6.1±2.8). The number of aforementioned visits compared to those between January and March 2016 also significantly decreased (p=0.01). Our results suggest that preventative information about climate and environmental changes provided by pharmacists during patient counseling might influence the number of asthma patient visits and prevent the exacerbation of their symptoms.

feedback
Top